Clinical Trials Logo

Filter by:
NCT ID: NCT03874013 Recruiting - Clinical trials for Growth Hormone Deficiency

Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone Deficiency

Start date: December 7, 2017
Phase: Phase 3
Study type: Interventional

Treatment of children with growth failure due to growth hormone deficiency (GHD). Primary • To evaluate the efficacy and safety of weekly MOD-4023 administration compared to daily Genotropin® administration in Japanese pre-pubertal children with GHD. Secondary • To evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) profiles of three different doses of MOD-4023 in Japanese pre-pubertal children with GHD.

NCT ID: NCT03873116 Recruiting - Clinical trials for Hereditary Angioedema, HAE

Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in Japan

APeX-J
Start date: February 28, 2019
Phase: Phase 3
Study type: Interventional

This is a phase 3, multi-center, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of oral BCX7353 in preventing acute angioedema attacks in patients with Type I and Type II HAE who live in Japan.

NCT ID: NCT03870087 Not yet recruiting - Clinical trials for Coronary Artery Disease

PRECISION GRX Post-Market Study - Japan

Start date: April 2019
Phase:
Study type: Observational [Patient Registry]

To collect data on the routine patterns of use, safety and effectiveness, including the clinical and technical performance of the CorPath GRX System, in the delivery and manipulation of coronary guidewires and stent/balloon catheters, and manipulation of guide catheters during PCI procedures in the first 231 patients treated with the CorPath device in Japan.

NCT ID: NCT03868267 Not yet recruiting - Clinical trials for Functional Dyspepsia

Japanese Upper GI Symptoms Compared With Iranian and Canadian Patients Presenting

Start date: April 10, 2019
Phase:
Study type: Observational [Patient Registry]

The purpose of this prospective cohort study is to compare upper GI symptoms and endoscopy findings in Canada with Japan and Iran, and correlate this with the upper GI microbiome. We plan to recruit 500 new patients referred for upper GI endoscopy in Canada (McMaster University) and 500 in Japan (Tohoku University Hospital) and 500 from Iran (Tehran University of Medical Sciences). Written consent will be obtained from all participants. Patients will complete three symptom questionnaires and a demographic one before endoscopy. Then saliva collection device will be applied for collecting saliva and microbiota from the oral cavity. Esophagogastroduodenoscopy (EGD) will be performed thereafter and brushing of the esophagus, stomach, and the duodenum will be done using a sterile sheathed brush (one for each site) to sample collect gut microbiota and gastric biopsies will be done for assessing H.pylori status. In addition, a group of these patients will undergo measurement of nitrate reductase activity (NRA) in their oral cavity. This will be done on twenty erosive gastro-esophageal reflux disease (GERD) patients, twenty non-erosive GERD patients, and twenty patients without any endoscopic or clinical GERD. This latter part of the study will be done at the Canadian and Iranian sites only. Bacterial community profiling of the 16S rRNA gene will be carried out using paired end reads of the V3 region. Triplicate amplifications will be pooled for 150 or 250 nt paired-end Illumina sequencing in the McMaster Genome Center. For specific substudies analysis of the mycome will also be carried out.

NCT ID: NCT03864484 Not yet recruiting - Clinical trials for Post-stroke Depression

iPad Application-based Intervention for Post-stroke Depression

Start date: April 1, 2019
Phase: N/A
Study type: Interventional

We plan to conduct a randomized controlled trial to examine whether usual rehabilitation plus an iPad application-based intervention improves post-stroke depression symptoms compared to usual rehabilitation alone. The purpose of this pilot randomized controlled trial is to investigate the feasibility of the final randomized controlled trial.

NCT ID: NCT03864458 Not yet recruiting - Hyperphosphatemia Clinical Trials

A Phase 2, Dose-finding Study of KHK7791 in Hyperphosphatemia Patients

Start date: March 2019
Phase: Phase 2
Study type: Interventional

To evaluate the effect and safety of KHK7791 to treat Hyperphosphatemia in ptatients on HD.

NCT ID: NCT03864445 Not yet recruiting - Hyperphosphatemia Clinical Trials

A Phase 2, Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients

Start date: March 2020
Phase: Phase 2
Study type: Interventional

To evaluate the effect and safety of KHK7791 in combination with phosphate binders to treat Hyperphosphatemia in ptatients on HD.

NCT ID: NCT03861052 Not yet recruiting - Type 2 Diabetes Clinical Trials

A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes

SURPASS J-mono
Start date: May 7, 2019
Phase: Phase 3
Study type: Interventional

The reason for this study is to see if the study drug tirzepatide (LY3298176) is effective and safe compared to dulaglutide in participants with type 2 diabetes in Japan.

NCT ID: NCT03861039 Not yet recruiting - Clinical trials for Type 2 Diabetes Mellitus

A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes

Start date: March 30, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the long-term safety of the study drug tirzepatide in combination with oral antihyperglycemic medications in participants with type 2 diabetes.

NCT ID: NCT03853798 Not yet recruiting - Clinical trials for Pyruvate Kinase Deficiency

Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007

Start date: March 14, 2019
Phase: Phase 3
Study type: Interventional

This is a multicenter, open-label, extension study to evaluate the long-term safety, tolerability, and efficacy of treatment with AG-348 in participants who were previously enrolled in Study AG348-C-006 or Study AG348C-007.